Nick Leschly has served as our chief bluebird since September . Formerly, Nick was a partner and founding member of Third Rock Ventures in . Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early stage drug development programs and served as the product leader for VELCADE..Derek Adams, Ph.D., joined us in March as our chief technology and manufacturing officer. Prior to joining bluebird, Derek was the senior vice president of . integration and operations at Change Healthcare Holdings, Inc. from November to April . For over years, Mr. Vachon held a variety of leadership .In addition, we are combining several strategic functions under Jeff s leadership to maintain our strategic focus in a rapidly evolving field. As a result, Jim has .
Related posts to leadership bluebird bio
He served as interim chief medical officer of bluebird bio in and previously served on the board of directors of the American Society for Human Genetics. Phil is currently a trustee of Cornell University and is a founding fellow .
Integrated Product Platforms with Broad The.utic Potential. We are leading the gene therapy revolution with integrated product platforms encompassing gene therapy, cancer immunotherapy and gene editing providing us with the potential to treat, and hopefully cure, a broad range of serious diseases..
Prior to joining bluebird, she worked at Alnylam Pharmaceuticals, Inc., holding increasing responsibilities for company strategy, business planning, portfolio and program management, alliance management, information technology and broader organizational capability building initiatives..
Bluebird bio is a clinical stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell based immunotherapies..